---
layout: post
title: "【图解年报】恒瑞医药：2021年归母净利润下降28.4%，降幅超营收"
date: 2022-04-22 19:26:03 +0800
categories: dongfangcaifuChoiceshuju
tags: 东方财富Choice数据新闻
---
<p>恒瑞医药于2022年4月23日披露年报，公司2021年实现营业总收入259.1亿，同比下降6.6%；实现归母净利润45.3亿，同比下降28.4%；每股收益为0.71元。</p><img id="image7" class="autoimg" src="https://dfscdn.dfcfw.com/download/D2588D7344F3E4BD5DBD0DCC0E244D8C1B_w800h400.jpg" alt=""><p style="color:#61768C;font-size:0.9em;"></p><img id="image9" class="autoimg" src="https://dfscdn.dfcfw.com/download/D20549B636600A2C7A035583E0408F6FA6_w800h400.jpg" alt=""><p><strong>期间费用率升高5.2%</strong></p><p>公司2021年营业成本37.4亿，同比上升11.7%，营业收入同比下降6.6%，毛利率下降2.4%。期间费用率为68.9%，较上年升高5.2%。</p><img id="image12" class="autoimg" src="https://dfscdn.dfcfw.com/download/D20D775C8023E5CDCE1C73D1FE2EC3DC2E_w800h400.jpg" alt=""><p><strong>本期“抗肿瘤药”营收贡献较大 </strong></p><p>从业务结构来看，“抗肿瘤药”是企业营业收入的主要来源。具体而言，“抗肿瘤药”营业收入为130.7亿，营收占比为50.7%，毛利率为90.7%。</p><img id="image15" class="autoimg" src="https://dfscdn.dfcfw.com/download/D24B6A1CBC903542DAFABAACF9CA9BD9D9_w800h400.jpg" alt=""><img id="image17" class="autoimg" src="https://dfscdn.dfcfw.com/download/D2BDC54B9F9F91B0C659CC982DBAE33AA3_w800h400.jpg" alt=""><p style="font-weight:bold;"></p><p style="margin: 10px 0; color: #999">免责声明：本文基于大数据生产，仅供参考，不构成任何投资建议，据此操作风险自担。</p><style>.autoimg {display: block;border: 0;max-width: 100%;margin: 0 auto;} .tbl {border-collapse: collapse;border-spacing: 0;text-align: center;width: 100% !important;} .tbl tr th, .tbl tr td {border: 1px solid #d8e6ff;padding: 5px;text-align: center;} .tbl tr th {color: #fff;background-color: #1c65b0;vertical-align: middle;} .tbl tr td {color: #000;background-color: #fff;} .imgtitle {text-indent: 0;text-align: center;color: #2395F1;} .autosrc {color: #999;display: block;text-align: center;margin-bottom: 5px;}</style>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204222354358085>

[返回东方财富Choice数据新闻](//finews.withounder.com/category/dongfangcaifuChoiceshuju.html)｜[返回首页](//finews.withounder.com/)